Skip to content
lifestyle.thenyctimes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Zhongshan Kangfang Biological Medicine Co., LTD
Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
March 4, 2026
Akeso’s IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications
February 12, 2026
Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer
February 11, 2026
Ivonescimab Included in FirstWord Pharma’s “The Drugs That Will Shape 2026”
January 29, 2026
Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis
January 19, 2026
Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer
January 14, 2026
Ivonescimab’s Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
January 6, 2026
←
Previous Page
1
2